ArticleNature genetics2017
A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.
Open access · greenAbstract read
In one paragraph
Article in Nature genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 212 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
212citing papers in PubMed, 1 pooled it
13.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
212 citing papers in PubMed, 1 synthesis or guideline pooled it, 363 citations in OpenAlex.
- The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol.Nature reviews. Urology · 2018Guideline
- Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- DGCR8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis.The Journal of clinical investigation · 2020Trial
- DNA Methylation and Transcriptomic Profiles of Wilms Tumour Reveal New Deregulated Genes and Epigenetic Processes Relevant for Tumour Stratification and Management.International journal of cancer · 2026Article
- Article
- Molecular Pathogenesis, Tumor Microenvironment and Health Disparities in Select Pediatric Solid Tumors: An Integrative Narrative Review.Diseases (Basel, Switzerland) · 2026Review
- Single-nucleus RNA sequencing reveals transcriptional heterogeneity in the blastema of favorable-histology Wilms tumor.JCI insight · 2026Article
- Trends and etiological profile of kidney cancer in China from 1990 to 2023: an analysis of modifiable risk factors and prevention implications using GBD 2023 estimates.International journal of clinical oncology · 2026Review
- Developmental timing distinguishes pediatric and adult cancers through retention and rewiring mechanisms.Nature communications · 2026Review
- Article
- Multi-omics and machine learning integration of diverse cell death pathways optimize risk stratification and inform drug therapy in Wilms tumor.Discover oncology · 2026Article
- Finding a brush when you expect a broom: a novel model of paediatric Wilms tumour evolution.Nature reviews. Urology · 2026Article
- Single-cell analysis reveals that NRG1/3-ERBB4 signaling affects metabolic reprogramming and immune escape in Wilms tumor.Biology direct · 2026Article
- Advances in targeted therapies for pediatric tumors.Acta pharmacologica Sinica · 2026Article
- Discovery of a Highly Potent and Selective ENL Degrader.Journal of medicinal chemistry · 2026Article
- Six1 haploinsufficiency is associated with activation of NF-κB and TNF-related transcriptional signatures in aging mice.Cell death & disease · 2026Article
- Genetic and Epigenetic Drivers of Wilms Tumor Predisposition in Russian Pediatric Patients: A Multicenter Study.International journal of molecular sciences · 2026Article
- Developmental reprogramming underlies chemotherapy resistance in favorable-histology Wilms tumor.Cell reports · 2026Article
- Capturing clinically actionable copy number alterations in Wilms tumor using nanopore sequencing.Research square · 2026Article
- A chemical-genetic interaction between PAF1 and ENL/AF9 YEATS inhibition.RSC chemical biology · 2026Article
152 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
31 authors at 10 institutions in 4 countries.
Samantha GaddDepartment of Pathology and Laboratory Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine and Robert H. Lurie Cancer Center, Chicago, Illinois, USA.
Vicki HuffDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Amy L WalzDivision of Hematology-Oncology and Transplantation, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Ariadne H A G OomsDepartment of Pathology and Laboratory Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine and Robert H. Lurie Cancer Center, Chicago, Illinois, USA.
Amy E ArmstrongDivision of Hematology-Oncology and Transplantation, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Daniela S GerhardOffice of Cancer Genomics, National Cancer Institute, Bethesda, Maryland, USA.
Malcolm A SmithCancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0001-9880-9876
Jaime M Guidry AuvilOffice of Cancer Genomics, National Cancer Institute, Bethesda, Maryland, USA.
Daoud MeerzamanCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland, USA.
Qing-Rong ChenCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland, USA.
Chih Hao HsuCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland, USA.
Chunhua YanCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland, USA.
Cu NguyenCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland, USA.
Ying HuCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland, USA.
Leandro C HermidaOffice of Cancer Genomics, National Cancer Institute, Bethesda, Maryland, USA.
Tanja DavidsenCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland, USA.
Patee GesuwanOffice of Cancer Genomics, National Cancer Institute, Bethesda, Maryland, USA.
Yussanne MaCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency (BCCA), Vancouver, British Columbia, Canada.
Zusheng ZongCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency (BCCA), Vancouver, British Columbia, Canada.
Andrew J MungallCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency (BCCA), Vancouver, British Columbia, Canada.ORCID 0000-0002-0905-2742
Richard A MooreCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency (BCCA), Vancouver, British Columbia, Canada.
Marco A MarraCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency (BCCA), Vancouver, British Columbia, Canada.
Jeffrey S DomeDivision of Pediatric Hematology/Oncology, Children's National Medical Center, Washington DC, USA.
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.ORCID 0000-0002-1871-1850
Jing MaDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
David A WheelerDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Oliver A HamptonDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Nicole RossDepartment of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Ohio State University College of Medicine, Columbus, Ohio, USA.
Julie M Gastier-FosterDepartment of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Ohio State University College of Medicine, Columbus, Ohio, USA.
Stefan T AroldComputational Bioscience Research Center, Division of Biological and Environmental Sciences and Engineering, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia.
Elizabeth J PerlmanDepartment of Pathology and Laboratory Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine and Robert H. Lurie Cancer Center, Chicago, Illinois, USA.ORCID 0000-0001-6853-6221
National Cancer Institute · USNorthwestern University · USCanada's Michael Smith Genome Sciences Centre · CABaylor College of Medicine · USNationwide Children's Hospital · USSt. Jude Children's Research Hospital · USChildren's National · USKing Abdullah University of Science and Technology · SAThe University of Texas MD Anderson Cancer Center · USUniversity of British Columbia · CA
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6MCOG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5MTumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LEONIDAS C. PLATANIAS · 1993 to 2026
$153.9MCOG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3MChildren's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ANDERSON, JAMES R · 2003 to 2013
$67.5MSupport for Human Specimen Banking in NCI-Supported Cancer Clinical TrialsU24CA114766 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RAMIREZ MILAN, NILSA DEL CARMEN · 2005 to 2014
$14.5MCLINICAL ONCOLOGY RESEARCH TRAINING PROGRAMT32CA079447 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LICHT, JONATHAN D. · 1999 to 2013
$3.1MCATEGORIZATION OF WILMS TUMOR BY GENETIC EXPRESSIONU01CA088131 · NCI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI PERLMAN, ELIZABETH J · 2001 to 2006
$1.7MCCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS P30 CA016058NCI NIH HHS P30 CA060553NCI NIH HHS T32 CA079447NCI NIH HHS U01 CA088131NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA114766
Abstract
We performed genome-wide sequencing and analyzed mRNA and miRNA expression, DNA copy number, and DNA methylation in 117 Wilms tumors, followed by targeted sequencing of 651 Wilms tumors. In addition to genes previously implicated in Wilms tumors (WT1, CTNNB1, AMER1, DROSHA, DGCR8, XPO5, DICER1, SIX1, SIX2, MLLT1, MYCN, and TP53), we identified mutations in genes not previously recognized as recurrently involved in Wilms tumors, the most frequent being BCOR, BCORL1, NONO, MAX, COL6A3, ASXL1, MAP3K4, and ARID1A. DNA copy number changes resulted in recurrent 1q gain, MYCN amplification, LIN28B gain, and MIRLET7A loss. Unexpected germline variants involved PALB2 and CHEK2. Integrated analyses support two major classes of genetic changes that preserve the progenitor state and/or interrupt normal development.
Indexed as
Genes, NeoplasmAneuploidyDNA MethylationEpigenesis, GeneticGene DosageGene Expression Regulation, NeoplasticGenome-Wide Association StudyGerm-Line MutationHumansKidney NeoplasmsMicroRNAsProtein ConformationRNA, MessengerRNA, NeoplasmWilms TumorMicroRNAsRNA, MessengerRNA, Neoplasm
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.